Luminor Medical Technologies Inc. (TSXV:LMT) (the “Company” or “Luminor Medical”) (formerly Miraculins Inc.) is pleased to announce that it has executed a letter of intent (the “LOI”) to acquire the exclusive Canadian and Jamaican licences for all current and future cannabis commercial products (the “Acquisition”) owned by Jamaica BLU Ltd. (“J-BLU”). J-BLU’s cannabis commercial products are based on a patent pending process to create precise cannabis-based formulations that produce specifically-targeted effects for various ailments and diseases including diabetes. Under the terms of the LOI, Luminor Medical will issue 9,500,000 common shares to the shareholders of J-BLU and $200,000 for intellectual property access. The issuance of the 9,500,000 common shares to the shareholders of J-BLU will not trigger a change of control scenario under the rules of the TSX Venture Exchange (the “TSXV”).
“J-BLU’s technological platform promises to create a wide variety of precise formulations that produce specifically-targeted effects for various types of patients, including people with diabetes. Patients and Health Care providers expect consistent high quality product produced by the best available practices and methods and that is just what J-BLU provides,” said Christian Sauvageau, CEO of Luminor Medical. “Although our primary interest is directed toward the J-BLU diabetes formulation, Luminor Medical will capitalise on every formulation developed for the Canadian and Jamaican markets.”
Under the terms of the LOI, Luminor Medical is required to raise a minimum of $4,000,000 in equity (the “Equity Financing”) of which up to $2,000,000 will be used to build a production facility and support the marketing of J-BLU’s initial cannabis-based products which support patients with low libido — Jamaicablū and Jamaicablū PNK.
Anton Mattadeen, President and CEO of J-BLU, stated, “We are very excited by this new partnership with Luminor Medical. The combination of their mission to improve the lives of people with health issues like diabetes and our proprietary formulations of cannabis has the potential to play an important role in offering a variety of highly efficacious solutions while addressing the rapidly growing demand for cannabis-based medical products around the world. It is our collective goal to take a leadership role in this area.”
The Acquisition is subject to a number of conditions, including but not limited to TSXV acceptance and the Equity Financing. There can be no assurance that the Acquisition of the Cannabis Products will be completed as proposed or at all.
About Jamaica BLU Ltd.
Jamaica BLU Ltd. is a private Ontario Corporation which has product formulation and branding provided under a worldwide exclusive licence. Their focus is the creation of cutting edge cannabis consumer products for both the medical and Adult-Use markets, as these markets emerge, around the world. The first group of Adult-Use consumer products leverages the well-known aphrodisiac qualities of cannabis to address both male and female sexual dysfunction by providing highly effective sexual enhancement formulations for both men and women, and will target the 26 million adults in Canada who may have a desire to improve their sex lives after Adult-Use cannabis is approved in Canada as expected in mid 2018.
Luminor Medical Technologies is a medical diagnostic company focused on acquiring, developing and commercializing medical technologies for unmet clinical needs. The Company’s Scout DS® device has been regulatory cleared in certain markets both as a clinical tool to assist in the identification of both prediabetes and type 2 diabetes, and is the first non-invasive testing system designed to provide a highly sensitive and convenient method for measuring prediabetes/type 2 diabetes related biomarkers in the skin, the accumulation of which are accelerated by abnormal blood sugar levels and oxidative stress. Unlike current testing methods, a Scout DS® test requires no blood draw, no fasting, and no waiting for a lab result. The product has been used and validated in thousands of patients around the world.
For more information, please contact:
President & CEO
Luminor Medical Technologies Inc.
Ph: (438) 889-3585
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
Certain statements contained in this media release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, “forward-looking statements”). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, outcomes related to the strategic review process the Company has been undergoing and any related outcomes as regards changes to the Company’s business plan and operations, as well as its planned stock consolidation and post-consolidation capital raise and can, in some cases, be identified by the use of words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Luminor‘s early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers’ willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Luminor’s filings with Canadian securities regulatory authorities, as well as Luminor’s ability to anticipate and manage the risks associated with the foregoing. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release. Luminor cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Luminor’s forward-looking statements to make decisions with respect to Luminor investors and others should carefully consider the foregoing factors and other uncertainties and potential events.
These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Lumionr cannot provide assurance that actual results will be consistent with these forward-looking statements. Luminor undertakes no obligation to update or revise any forward-looking statements except as may be required by law.
Scout DS® is a registered trademark of Luminor Medical Technologies Inc. All Rights Reserved. 2016.
Source: New feed